135 related articles for article (PubMed ID: 31902844)
1. [Multiple consequences of HIF activation in CKD].
Tanaka T
Nihon Yakurigaku Zasshi; 2020; 155(1):30-34. PubMed ID: 31902844
[TBL] [Abstract][Full Text] [Related]
2. Expanding roles of the hypoxia-response network in chronic kidney disease.
Tanaka T
Clin Exp Nephrol; 2016 Dec; 20(6):835-844. PubMed ID: 26857707
[TBL] [Abstract][Full Text] [Related]
3. HIF Activation Against CVD in CKD: Novel Treatment Opportunities.
Tanaka T; Eckardt KU
Semin Nephrol; 2018 May; 38(3):267-276. PubMed ID: 29753402
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease.
Hasegawa S; Tanaka T; Nangaku M
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):331-338. PubMed ID: 30067604
[TBL] [Abstract][Full Text] [Related]
5. The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration.
Yu X; Fang Y; Liu H; Zhu J; Zou J; Xu X; Jiang S; Ding X
Nephrol Dial Transplant; 2012 Aug; 27(8):3110-9. PubMed ID: 22399494
[TBL] [Abstract][Full Text] [Related]
6. Preconditioned suppression of prolyl-hydroxylases attenuates renal injury but increases mortality in septic murine models.
Schindler K; Bondeva T; Schindler C; Claus RA; Franke S; Wolf G
Nephrol Dial Transplant; 2016 Jul; 31(7):1100-13. PubMed ID: 26908768
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
Sakashita M; Tanaka T; Nangaku M
Contrib Nephrol; 2019; 198():112-123. PubMed ID: 30991411
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-Inducible Factor and Oxygen Biology in the Kidney.
Sugahara M; Tanaka T; Nangaku M
Kidney360; 2020 Sep; 1(9):1021-1031. PubMed ID: 35369554
[TBL] [Abstract][Full Text] [Related]
9. A mechanistic link between renal ischemia and fibrosis.
Tanaka T
Med Mol Morphol; 2017 Mar; 50(1):1-8. PubMed ID: 27438710
[TBL] [Abstract][Full Text] [Related]
10. The protective effect of prolyl-hydroxylase inhibition against renal ischaemia requires application prior to ischaemia but is superior to EPO treatment.
Wang Z; Schley G; Türkoglu G; Burzlaff N; Amann KU; Willam C; Eckardt KU; Bernhardt WM
Nephrol Dial Transplant; 2012 Mar; 27(3):929-36. PubMed ID: 21742784
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.
Kaplan JM; Sharma N; Dikdan S
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382128
[TBL] [Abstract][Full Text] [Related]
12. Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases.
Miao M; Wu M; Li Y; Zhang L; Jin Q; Fan J; Xu X; Gu R; Hao H; Zhang A; Jia Z
Front Pharmacol; 2022; 13():837249. PubMed ID: 35281917
[TBL] [Abstract][Full Text] [Related]
13. Transient hypoxia-inducible factor activation in rat renal ablation and reduced fibrosis with L-mimosine.
Yu X; Fang Y; Ding X; Liu H; Zhu J; Zou J; Xu X; Zhong Y
Nephrology (Carlton); 2012 Jan; 17(1):58-67. PubMed ID: 21777345
[TBL] [Abstract][Full Text] [Related]
14. [Current insights into the role of HIF-PHD axis in renal anemia].
Cao JY; Liu BC
Sheng Li Xue Bao; 2018 Dec; 70(6):623-629. PubMed ID: 30560271
[TBL] [Abstract][Full Text] [Related]
15. Alteration of the DNA Methylation Signature of Renal Erythropoietin-Producing Cells Governs the Sensitivity to Drugs Targeting the Hypoxia-Response Pathway in Kidney Disease Progression.
Sato K; Kumagai N; Suzuki N
Front Genet; 2019; 10():1134. PubMed ID: 31798631
[TBL] [Abstract][Full Text] [Related]
16. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia, HIF, and Associated Signaling Networks in Chronic Kidney Disease.
Liu J; Wei Q; Guo C; Dong G; Liu Y; Tang C; Dong Z
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468297
[TBL] [Abstract][Full Text] [Related]
18. The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia.
Landau D; London L; Bandach I; Segev Y
PLoS One; 2018; 13(5):e0196684. PubMed ID: 29738538
[TBL] [Abstract][Full Text] [Related]
19. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.
Maxwell PH; Eckardt KU
Nat Rev Nephrol; 2016 Mar; 12(3):157-68. PubMed ID: 26656456
[TBL] [Abstract][Full Text] [Related]
20. Role of hypoxia in progressive chronic kidney disease and implications for therapy.
Shoji K; Tanaka T; Nangaku M
Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):161-8. PubMed ID: 24378776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
